Summary
- Inozyme Pharma has filed to raise $75 million in a U.S. IPO.
- The firm is developing treatments for abnormal calcification conditions.
- INZY is still at a very early stage of development, so the IPO is ultra-high-risk and may be more suited to institutional investors.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today ยป
Quick Take
Inozyme Pharma (INZY) intends to raise $75 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing treatments for abnormal calcification in humans.
INZY is just preparing to enter Phase 1 trials for its lead programs, so the company is still at a very early and risky stage of development that may be more suited to institutional investors with long-term hold time frames.
Company & Technology
Boston, Massachusetts-based Inozyme was founded to advance treatments for defective gene expression of the ENPP1 and ABCC6 genes that produce increased arterial calcification and other deleterious calcium deposition effects throughout the body in the vasculature, soft tissue and skeleton.
Management is headed by president and Chief Executive Officer Mr. Axel Bolte, who has been with the firm since 2015 and was previously managing member of a healthcare advisory firm and venture partner at HBM Partners, AG.
Below is a brief overview video of a coronary calcification:
